Uued Systane Complete nanotehnoloogiaga silmatilgad

Apteekidesse on jõudnud uued, innovatiivsed SYSTANE® COMPLETE niisutavad silmatilgad. Tootes on kasutusel Alconi kõige uuem nanotehnoloogia silmade libestamiseks ja niisutamiseks, mis annab parema silma pinna katmise.^1-2,9*

Vaata eestikeelset tutvustavat videot SIIT.

Uudsed, lipiidsed nanosuuruses osakesed libestavad silma pinda kiiresti – tulemuseks on parem katvus,* et tagada kiire niisutus ja niiskuse säilitamine pikaajaliseks leevenduseks.^{1-2,4-5,17-18} SYSTANE® COMPLETE ei tekita tänu nanoosakestele vahetult peale silma tilgutamist udust nägemist.¹

SYSTANE® COMPLETE leevendab sümptomeid nagu kuivus, väsimus, ärritus, võõrkeha tunne, põletustunne, sügelus, punasus, pisaravool, rähmasus. Kaitseb silmi pikaajalisel ekraanide kasutamisel.

SYSTANE® COMPLETE´is on ühendatud SYSTANE® ULTRA ja SYSTANE® BALANCE peamised toimeained ja omadused ÜHTE leevendavasse silmatilka igat tüüpi kuiva silmale.^1-5,9-13

• Loodud kõikide kuiva silma tüüpide jaoks^1-5

• Uudsed nanoosakesed katavad paremini* silma pinda tagades kiire niisutuse ja pikaajalise leevenduse^{1-2,4-5,17-18}

• Toetab kõiki pisarakile kihte ja kaitseb aurustumise eest^17,19-21

Referentsid:

*Võrreldes SYSTANE® BALANCE´iga

1. Ketelson H, Rangarajan R. Pre-clinical evaluation of a novel phospholipid nanoemulsion based lubricant eye drops. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 7–11, 2017; Baltimore, Maryland, USA.

2. Data on file. Alcon; 2017.

3. Craig J, Nichols K, Akpek E, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276-283.

4. Lane S, Paugh JR, Webb JR, Christensen MT. An evaluation of the in vivo retention time of a novel artificial tear as compared to a placebo control. Poster presented at: The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 3-7, 2009; Fort Lauderdale, FL.

5. Benelli U. Systane® lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783-790.

6. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478.

7. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71-82.

8. Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010;51(7):3449-3454.

9. Data on file. Alcon; 2017.

10. SYSTANE® BALANCE [packaging]. Fort Worth, TX: Alcon Laboratories, Inc.; 2010.

11. SYSTANE® ULTRA [packaging]. Fort Worth, TX: Alcon Laboratories, Inc.; 2013.

12. SYSTANE® COMPLETE [packaging]. Fort Worth, TX: Alcon Laboratories, Inc.; 2017.

13. Fernandez KB, Epstein SP, Raynor GS, et al. Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution. Clin Ophthalmol. 2015;9:1137-1145.

14. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802-812.

15. Tear Film & Ocular Surface Society. http://www.tearfilm.org/dettreports-tfos_dews_ii_ report/32_30/eng/. Accessed April 5, 2018.

16. United States National Nanotechnology Initiative. https://www.nano.gov/nanotech-101/special. Accessed April 5, 2018.

17. Korb D, Blackie C, Meadows D, Christensen M, Tudor M. Evaluation of extended tear stability by two emulsion based artificial tears. Poster presented at: 6th International Conference of the Tear Film and Ocular Surface: Basic Science and Clinical Relevance; September 22-25, 2010; Florence, Italy.

18. Torkildsen G. The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test. Clin Ophthalmol. 2009;3:501-506.

19. Davitt, WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347-353.

20. Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15:366-403.

21. Moon SW, Hwang JH, Chung SH, Nam KH. The impact of artificial tears containing hydroxypropyl guar on mucous layer. Cornea. 2010;29(12):1430-1435.

22. Data on file. Alcon; 2014.